<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39373096</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-2995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Spike and nucleocapsid antibody dynamics following SARS-CoV-2 infection and vaccination: Implications for sourcing COVID-19 convalescent plasma from routinely collected blood donations.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/trf.18017</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 convalescent plasma (CCP) remains a treatment option for immunocompromised patients; however, the current FDA qualification threshold of ≥200 BAU/mL of spike antibody appears to be relatively low. We evaluated the levels of binding (bAb) and neutralizing antibodies (nAb) on serial samples from repeat blood donors who were vaccinated and/or infected to inform criteria for qualifying CCP from routinely collected plasma components.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Donors were categorized into four groups: (1) infected, then vaccinated, (2) vaccinated then infected during the delta, or (3) omicron waves, (4) vaccinated without infection. IgG Spike and total Nuclecapsid bAb were measured, along with S variants and nAb titers using reporter viral particle neutralization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean S IgG bAb peaks after infection alone were lower than after primary and booster vaccinations, and higher after delta and omicron infection in previously vaccinated donors. Half-lives for S IgG ranged from 34 to 66 days after first infection/vaccination events and up to 108 days after second events. The levels of S IgG bAb and nAb were similar across different variants, except for omicron, which were lower. Better correlations of nAb with bAb were observed at higher levels (hybrid immunity) than at the current FDA CCP qualifying threshold.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Routine plasma donations from donors with hybrid immunity had high S bAb and potent neutralizing activity for 3-6 months after infection. In donations with high (&gt;4000 BAU/mL) S IgG, &gt;95% had high nAb titers (&gt;500) against ancestral and variant S, regardless of COVID-19 symptoms. These findings provide the basis for test-based criteria for qualifying CCP from routine blood donations.</AbstractText><CopyrightInformation>© 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Germanio</LastName><ForeName>Clara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6047-211X</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xutao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balasko</LastName><ForeName>Brendan G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Graham</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9615-7023</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grebe</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7046-7245</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Mars</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Bryan R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-9008-9154</Identifier><AffiliationInfo><Affiliation>American Red Cross, Scientific Affairs, Dedham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saa</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6077-4532</Identifier><AffiliationInfo><Affiliation>American Red Cross, Scientific Affairs, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Elaine A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanteri</LastName><ForeName>Marion C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Creative Testing Solutions, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Creative Testing Solutions, Tempe, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Westat, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Westat, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of British Columbia, Victoria, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Jefferson</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4974-9058</Identifier><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biggerstaff</LastName><ForeName>Brad J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contestable</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ortho Clinical Diagnostics, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-1446-125X</Identifier><AffiliationInfo><Affiliation>Vitalant Research Institute, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75D30120C08170</GrantID><Agency>Quidel-Ortho</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immunology (other than RBC serology)</Keyword><Keyword MajorTopicYN="N">infectious disease testing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373096</ArticleId><ArticleId IdType="doi">10.1111/trf.18017</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Fendler A, de Vries EGE, GeurtsvanKessel CH, Addeo A, Baumeister S, Marra A, et al. COVID‐19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19:385–401. https://doi.org/10.1038/s41571-022-00610-8</Citation></Reference><Reference><Citation>Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, et al. How to provide the needed protection from COVID‐19 to patients with hematologic malignancies. Blood Cancer Discov. 2021;2(6):562–567. https://doi.org/10.1158/2643-3230.BCD-21-0166</Citation></Reference><Reference><Citation>Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, et al. Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019. Clin Infect Dis off Publ Infect Dis Soc Am. 2023;76(11):2018–2024. https://doi.org/10.1093/cid/ciad066</Citation></Reference><Reference><Citation>Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID‐19. eClinicalMedicine. 2023;59:101965. https://doi.org/10.1016/j.eclinm.2023.101965</Citation></Reference><Reference><Citation>Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID‐19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta‐analysis. JAMA Netw Open. 2023;6(1):e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647</Citation></Reference><Reference><Citation>Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID‐19. Nat Rev Immunol. 2021;21(6):382–393. https://doi.org/10.1038/s41577-021-00542-x</Citation></Reference><Reference><Citation>Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS‐CoV‐2. Lancet Infect Dis. 2022;22(11):e311–e326. https://doi.org/10.1016/S1473-3099(22)00311-5</Citation></Reference><Reference><Citation>Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of immune escape variants from antibody‐based therapeutics against COVID‐19: a systematic review. Int J Mol Sci. 2021;23(1):29. https://doi.org/10.3390/ijms23010029</Citation></Reference><Reference><Citation>VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, et al. An infectious SARS‐CoV‐2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28:490–495. https://doi.org/10.21203/rs.3.rs-1175516/v1</Citation></Reference><Reference><Citation>Ragonnet‐Cronin M, Nutalai R, Huo J, Dijokaite‐Guraliuc A, das R, Tuekprakhon A, et al. Generation of SARS‐CoV‐2 escape mutations by monoclonal antibody therapy. Nat Commun. 2023;14:3334. https://doi.org/10.1038/s41467-023-37826-w</Citation></Reference><Reference><Citation>Anti‐SARS‐CoV‐2 Monoclonal Antibodies. COVID‐19 treatment guidelines. Accessed March 27, 2024. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals‐including‐antibody‐products/anti‐sars‐cov‐2‐monoclonal‐antibodies/</Citation></Reference><Reference><Citation>Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, et al. Convalescent plasma for people with COVID‐19: a living systematic review. Cochrane Database Syst Rev. 2023;2023:2. https://doi.org/10.1002/14651858.CD013600.pub5</Citation></Reference><Reference><Citation>Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent plasma in COVID‐19 patients with immunosuppression. Transfusion (Paris). 2021;61(8):2503–2511. https://doi.org/10.1111/trf.16525</Citation></Reference><Reference><Citation>Li M, Beck EJ, Laeyendecker O, Eby Y, Tobian AAR, Caturegli P, et al. Convalescent plasma with a high level of virus‐specific antibody effectively neutralizes SARS‐CoV‐2 variants of concern. Blood Adv. 2022;6(12):3678–3683. https://doi.org/10.1182/bloodadvances.2022007410</Citation></Reference><Reference><Citation>Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct early serological signatures track with SARS‐CoV‐2 survival. Immunity. 2020;53(3):524–532.e4. https://doi.org/10.1016/j.immuni.2020.07.020</Citation></Reference><Reference><Citation>Immunocompromised. COVID‐19 treatment guidelines. Accessed march 27, 2024. https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/</Citation></Reference><Reference><Citation>Research C for BE. Investigational COVID‐19 convalescent plasma. Published October 13, 2023. Accessed March 27, 2024 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma</Citation></Reference><Reference><Citation>Crotty S. Hybrid immunity. Science. 2021;372(6549):1392–1393. https://doi.org/10.1126/science.abj2258</Citation></Reference><Reference><Citation>Jones JM, Manrique IM, Stone MS, Grebe E, Saa P, Germanio CD, et al. Estimates of SARS‐CoV‐2 Seroprevalence and incidence of primary SARS‐CoV‐2 infections among blood donors, by COVID‐19 vaccination status ‐ United States, April 2021‐September 2022. MMWR Morb Mortal Wkly Rep. 2023;72(22):601–605. https://doi.org/10.15585/mmwr.mm7222a3</Citation></Reference><Reference><Citation>Di Germanio C, Simmons G, Thorbrogger C, Martinelli R, Stone M, Gniadek T, et al. Vaccination of COVID‐19 convalescent plasma donors increases binding and neutralizing antibodies against SARS‐CoV‐2 variants. Transfusion (Paris). 2022;62(3):563–569. https://doi.org/10.1111/trf.16823</Citation></Reference><Reference><Citation>Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, et al. SARS‐CoV‐2 antibody persistence in COVID‐19 convalescent plasma donors: dependency on assay format and applicability to serosurveillance. Transfusion (Paris). 2021;61(9):2677–2687. https://doi.org/10.1111/trf.16555</Citation></Reference><Reference><Citation>Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed‐effects models using lme4. J Stat Softw. 2015;67:1–48. https://doi.org/10.18637/jss.v067.i01</Citation></Reference><Reference><Citation>Shrotri M, Fragaszy E, Nguyen V, Navaratnam AMD, Geismar C, Beale S, et al. Spike‐antibody responses to COVID‐19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat Commun. 2022;13(1):5780. https://doi.org/10.1038/s41467-022-33550-z</Citation></Reference><Reference><Citation>Stone M, Grebe E, Sulaeman H, di Germanio C, Dave H, Kelly K, et al. Evaluation of commercially available high‐throughput SARS‐CoV‐2 serologic assays for Serosurveillance and related applications. Emerg Infect Dis. 2022;28(3):672–683. https://doi.org/10.3201/eid2803.211885</Citation></Reference><Reference><Citation>Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS‐CoV‐2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021;7(31):eabh3409. https://doi.org/10.1126/sciadv.abh3409</Citation></Reference><Reference><Citation>Ghafari M, Hall M, Golubchik T, Ayoubkhani D, House T, MacIntyre‐Cockett G, et al. Prevalence of persistent SARS‐CoV‐2 in a large community surveillance study. Nature. 2024;626(8001):1094–1101. https://doi.org/10.1038/s41586-024-07029-4</Citation></Reference><Reference><Citation>Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, le Bert N, et al. Dynamics of SARS‐CoV‐2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240–e249. https://doi.org/10.1016/S2666-5247(21)00025-2</Citation></Reference><Reference><Citation>Zhou Z, Barrett J, He X. Immune imprinting and implications for COVID‐19. Vaccine. 2023;11(4):875. https://doi.org/10.3390/vaccines11040875</Citation></Reference><Reference><Citation>Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Coyle P, Yassine HM, et al. Immune imprinting and protection against repeat reinfection with SARS‐CoV‐2. N Engl J Med. 2022;387(18):1716–1718. https://doi.org/10.1056/NEJMc2211055</Citation></Reference><Reference><Citation>Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, et al. Memory B cell repertoire from triple vaccinees against diverse SARS‐CoV‐2 variants. Nature. 2022;603(7903):919–925. https://doi.org/10.1038/s41586-022-04466-x</Citation></Reference><Reference><Citation>Park YJ, Pinto D, Walls AC, Liu Z, de Marco A, Benigni F, et al. Imprinted antibody responses against SARS‐CoV‐2 omicron sublineages. Science. 2022;378(6620):619–627. https://doi.org/10.1126/science.adc9127</Citation></Reference><Reference><Citation>Monge S, Pastor‐Barriuso R, Hernán MA. The imprinting effect of covid‐19 vaccines: an expected selection bias in observational studies. BMJ. 2023;381:e074404. https://doi.org/10.1136/bmj-2022-074404</Citation></Reference><Reference><Citation>Yisimayi A, Song W, Wang J, Jian F, Yu Y, Chen X, et al. Repeated omicron exposures override ancestral SARS‐CoV‐2 immune imprinting. Nature. 2024;625(7993):148–156. https://doi.org/10.1038/s41586-023-06753-7</Citation></Reference><Reference><Citation>Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Krüger K, et al. Omicron breakthrough infection drives cross‐variant neutralization and memory B cell formation. 2022;7(75):eabq2427. https://doi.org/10.1101/2022.04.01.486695</Citation></Reference><Reference><Citation>Kissler SM, Hay JA, Fauver JR, Mack C, Tai CG, Anderson DJ, et al. Viral kinetics of sequential SARS‐CoV‐2 infections. Nat Commun. 2023;14(1):6206. https://doi.org/10.1038/s41467-023-41941-z</Citation></Reference><Reference><Citation>Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, et al. Neutralization, effector function and immune imprinting of omicron variants. Nature. 2023;621(7979):592–601. https://doi.org/10.1038/s41586-023-06487-6</Citation></Reference><Reference><Citation>Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, et al. COVID‐19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022;35(3):e0020021. https://doi.org/10.1128/cmr.00200-21</Citation></Reference><Reference><Citation>Romera Martínez I, Avendaño‐Solá C, Villegas Da Ros C, Bosch Llobet A, García Erce JA, González Fraile MI,et al. Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial. Vox Sang. 2024;119(1):27–33. https://doi.org/10.1111/vox.13561</Citation></Reference><Reference><Citation>Ripoll JG, Tulledge‐Scheitel SM, Stephenson AA, Ford S, Pike ML, Gorman EK, et al. outpatient treatment with concomitant vaccine‐boosted convalescent plasma for patients with immunosuppression and COVID‐19. mBio. 2024;15(5):e0040024. https://doi.org/10.1101/2023.08.29.23293790</Citation></Reference><Reference><Citation>Inbar T, Dann EJ, Kerner O, Stern A. Charting a path forward: promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19. Transfusion. 2024;64(3):443–448. https://doi.org/10.1111/trf.17737</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>